Clinical trial · Interventional
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
Phase II Study of Avastin Plus Erbitux Plus Irinotecan as 2nd Line Treatment of Locally Advanced or Metastatic Colorectal Cancer in Patients Achieving Disease Progression as Best Response After 1st Line Treatment With FOLFIRI+Avastin or XELIRI+Avastin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to poor accrual
Summary
Brief summary (as posted)
This phase II study will evaluate the efficacy of the combination of two monoclonal antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed after 1st line treatment with FOLFIRI Avastin or XELIRI Avastin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avastin | Drug | Bevacizumab | ALIAS |
| Erbitux | Drug | Cetuximab | ALIAS |
| Irinotecan | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Irinotecan+Avastin+Erbitux
- interventionNames
- Drug: Irinotecan
- Drug: Avastin
- Drug: Erbitux
Primary outcomes (1)
- measure
- Time To Progression
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- Objective Response Rate
- timeFrame
- Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)
- measure
- Toxicity profile
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed locally advanced or metastatic colorectal cancer. * Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) * ECOG performance status ≤ 2 * Age 18 - 72 years * Patients with de novo refractory disease (progression of disease as best response at 1st line therapy with FOLFOX/Avastin) * Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function * Patients must be able to understand the nature of this study * Written informed consent Exclusion Criteria: * History of serious cardiac disease (unstable angina, congestive heart failure, uncontrolled cardiac arrhythmias). * History of myocardial infarction or stroke within 6 months. * Clinically significant peripheral vascular disease. * History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0. * Presence of central nervous system or brain mets. * Evidence of bleeding diathesis or coagulopathy. * Patients with known hypersensitive reaction to cetuximab * Blood pressure \> 150/100 mmHg. * Pregnant or lactating woman. * Life expectancy \< 3 months. * Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow. * Metastatic infiltration of the liver \>50%. * Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy. * Active infection requiring antibiotics on Day 1. * Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer. * Psychiatric illness or social situation that would preclude study compliance.
References
Publications (0)
Data not yet available